Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort studyResearch in context

Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort studyResearch in context

Summary: Background: Sézary syndrome is an extremely rare and fatal cutaneous T-cell lymphoma (CTCL). Mogamulizumab, an anti-CCR4 monoclonal antibody, has recently been associated with increased progression-free survival in a randomized clinical trial in CTCL. We aimed to evaluate OS and prognostic...

Full description

Bibliographic Details
Main Authors: Alizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, Michel D’Incan, Gaëlle Quereux, Emmanuella Guenova, Marie Perier-Muzet, Stephane Dalle, Florent Grange, Manuelle-Anne Viguier, Caroline Ram-Wolff, Laurence Feldmeyer, Helmut Beltraminelli, Nathalie Bonnet, Florent Amatore, Eve Maubec, Nathalie Franck, Laurent Machet, François Chasset, Florence Brunet-Possenti, Jean-David Bouaziz, Maxime Battistella, Marie Donzel, Anne Pham-Ledard, Claudia Bejar, Hélène Moins-Teisserenc, Samia Mourah, Philippe Saiag, Ewa Hainaut, Catherine Michel, Guido Bens, Henri Adamski, François Aubin, Serge Boulinguez, Pascal Joly, Billal Tedbirt, Isabelle Templier, Laura Troin, Henri Montaudié, Saskia Ingen-Housz-Oro, Sarah Faiz, Laurent Mortier, Gabor Dobos, Martine Bagot, Matthieu Resche-Rigon, Claire Montlahuc, Arnaud Serret-Larmande, Adèle de Masson
Format: Article
Language:English
Published: Elsevier 2024-07-01
Series:EClinicalMedicine
Subjects:
Cutaneous T-cell lymphoma
Sézary syndrome
Mogamulizumab
Monoclonal antibody
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S258953702400258X

Internet

http://www.sciencedirect.com/science/article/pii/S258953702400258X

Similar Items